Dia: 2 de junho de 2023

Perfil de risco-benefício favorável de Trastuzumab Deruxtecan em pacientes com MBC HER2-positivo que foram previamente tratados com Trastuzumab Emtansine

Notícia

2 de junho, 2023 Redação Oncologia Brasília Nenhum Comentário

Uma nova pesquisa publicada na revista Annals of Oncology descobriu que o Trastuzumab Deruxtecan tem um perfil de risco-benefício favorável em pacientes com câncer de […]

Continue lendo

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.

Necessary

Sempre ativado

Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.

Cookie	Duração	Descrição
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

Seja um membro

Login

Dia: 2 de junho de 2023

Perfil de risco-benefício favorável de Trastuzumab Deruxtecan em pacientes com MBC HER2-positivo que foram previamente tratados com Trastuzumab Emtansine

Institucional

Conteúdo

Redes Socias

Políticas de Privacidade

Aviso Legal

Feito por Listlead